ScreenerHero

BTMDBiote Corp. Class A Common Stock

NAS · US · Healthcare · Medical Care Facilities · biote.com
1.610USD+18.38%Mkt Cap: 54.58M $P/E: 11.50

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men …

Industry Peers

Medical Care Facilities
Screen all
HCA
HCA Healthcare, Inc.
$95.21BUSDP/E 14.4
FRE
Fresenius SE & Co. KGaA
$28.53BUSDP/E 16.8
THC
Tenet Healthcare Corporation
$22.61BUSDP/E 10.9
FME
Fresenius Medical Care AG & Co. KGaA
$11.72BUSDP/E 12.1
FMS
Fresenius Medical Care AG & Co. KGaA
$12.47BUSDP/E 12.2
EHC
Encompass Health Corporation
$11.87BUSDP/E 20.1
DVA
DaVita Inc.
$11.16BUSDP/E 14.7
ENSG
The Ensign Group, Inc.
$10.46BUSDP/E 28.1
UHS
Universal Health Services, Inc. Class B
$10.45BUSDP/E 7.2
CHE
Chemed Corporation
$7.07BUSDP/E 27.2
PACS
PACS Group Inc.
$7.00BUSDP/E 25.9
LFST
LifeStance Health Group Inc. Common Stock
$4.76BUSDP/E 95.9
CON
Concentra Group Holdings Parent Inc. Common Stock
$4.46BUSDP/E 22.6
MCOV-B
Medicover AB (publ)
$3.50BUSDP/E 39.0
NHC
National HealthCare Corporation
$3.66BUSDP/E 26.2
OPCH
Option Care Health, Inc.
$3.55BUSDP/E 18.0
AVAH
Aveanna Healthcare Holdings Inc.
$2.87BUSDP/E 10.3
BKD
Brookdale Senior Living Inc.
$2.82BUSD
EMEIS
Emeis SA
$2.45BUSD
ACHC
Acadia Healthcare Company, Inc.
$2.59BUSD
HeadlineSourceTime
Older
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ...

Despite a 9.5% revenue decline and revised guidance, Biote Corp (BTMD) focuses on operational recovery, supply normalization, and inorganic growth opportunities.

GuruFocus.com
biote Corp. (BTMD) Reports Break-Even Earnings for Q2

biote Corp. (BTMD) delivered earnings and revenue surprises of -100.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
biote Q2 Earnings Call Highlights

biote (NASDAQ:BTMD) reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half

MarketBeat
How The Evolving Story For biote (BTMD) May Shape Future Investor Expectations
Simply Wall St.